In a significant move poised to reshape the landscape of mental health treatment, U.S. President Donald Trump has signed an…
Read More
Cochrane Review Challenges Clinical Significance of Anti-Amyloid Alzheimer’s Drugs, Pharmaceutical Companies Reaffirm Efficacy
A comprehensive review of 17 clinical trials by the esteemed Cochrane organization has cast doubt on the clinically meaningful benefits…
Read More
FDA Reverses Course, Agrees to Review Moderna’s mRNA Flu Vaccine
The U.S. Food and Drug Administration (FDA) has officially reversed its earlier decision regarding Moderna’s investigational mRNA influenza vaccine (mRNA-1010),…
Read More
FDA Proposes Permanent Authorization of Rare Pediatric Disease Priority Review Voucher Program to Foster Regulatory Stability
The United States Food and Drug Administration (FDA) is making a significant move to permanently authorize the rare pediatric disease…
Read More
FDA Reverses Course, Agrees to Review Moderna’s mRNA Flu Vaccine
The U.S. Food and Drug Administration (FDA) has officially reversed its earlier stance on Moderna’s innovative mRNA influenza vaccine candidate,…
Read More
FDA Refuses to Review Moderna’s mRNA Flu Vaccine Application, Citing Comparator Study Design
Washington D.C. – Moderna, a leading biotechnology company, has announced that the U.S. Food and Drug Administration (FDA) has issued…
Read More
FDA Reverses Course, Agrees to Review Moderna’s mRNA Flu Vaccine
In a significant development for vaccine innovation and public health, the U.S. Food and Drug Administration (FDA) has reversed its…
Read More
FDA refuses to review Moderna’s mRNA flu vaccine
Moderna, a leading biotechnology company known for its pioneering work in mRNA technology, has been dealt a significant setback by…
Read More
FDA reverses course, agrees to review Moderna’s mRNA flu vaccine
The U.S. Food and Drug Administration (FDA) has officially reversed its earlier stance, agreeing to review Moderna’s messenger RNA (mRNA)…
Read More
